CLHIA-ACCAP

- actively engaged with the Patented Medicine Prices Review Board on its Guideline Modernization consultation and has made an industry submission that recommends a number of changes geared towards lowering prices in Canada. The second phase of the consultation is expected by June 2017 and should clarify the direction the government is considering. The CLHIA will actively participate in any discussions. - continued to strengthen its relationship with the pan-Canadian Pharmaceutical Alliance (pCPA). The CLHIA is continually discussing with pCPA further opportunities for collaboration on biosimilars following their commitment in 2016 to negotiate lower prices on all new biosimilars and to ensure that the negotiated price will apply to Canadians equally. c While it appears the government will not be proceeding with further work on the proposed new orphan drug regime at this time or roll out new regulations, the CLHIA will continue to look for opportunities to collaborate with the provinces to negotiate lower prices for orphan drugs in Canada. ACCAP-Quebec c ACCAP-Quebec completed its first full year of operation and during that time worked with member companies, regulators in the province and other stakeholders to identify and address a number of areas of mutual interest. A great deal was achieved including obtaining greater transparency on the invoices issued by pharmacists; a second very successful Quebec Advocacy Day this April; and supporting the Quebec government on their tour Relationships continue to deepen with all levels of government to advocate for measures to reduce the price of drugs in Canada so they are more in line with international prices ACCAP-Quebec has developed and implemented its own Strategic Plan to address the priorities of Quebec members A Message from the President and CEO Board of Directors Review of the Year's Results CLHIA Code of Member Service Members CLHIA Officers Chair's Message

• Cover